ANGPTL3 and coronary artery disorder: This result suggests that ANGPTL3 inhibition may be an exception to the LDL paradigm, the mechanism-independent log-linear relationship between LDL-C lowering and coronary disease protection that has been consistently found in genetic studies and clinical trials.42,46 In phase 1 trials, ANGPTL3 inhibitors reduced LDL-C levels by amounts similar to or greater than currently approved LDL-C–lowering drugs.6,20,21 Our findings suggest that ANGPTL3 inhibitors may be more effective than current agents for a given magnitude of LDL-C reduction.